Evaluation of Silibinin Effect on U-CH2 and MCF-7 Cell Lines through xCELLigence System (original) (raw)
Related papers
Asian Pacific journal of cancer prevention : APJCP, 2016
Silibinin is a natural polyphenol with high antioxidant and anticancer properties. In this study, its influence on two of the most commonly employed human breast cancer cell lines, MCF-7 and T47D, and one non-malignant MCF-10A cell line, were investigated and compared. Cell viability, the cell cycle distribution and apoptosis induction were analyzed by MTT and flow cytometry, respectively. The effect of silibinin on PTEN, Bcl-2, P21, and P27 mRNAs expression was also investigated by real-time RT-PCR. It was found that silibinin caused G1 cell cycle arrest in MCF-7 and MCF-10A cells but had no effect on the T47D cell cycle. Silibinin induced cytotoxic and apoptotic effects in T47D cells more than the MCF-7 cells and had no cytotoxic effect in MCF-10A cells under the same conditions. Silibinin upregulated PTEN in MCF-7 and caused slightly increased P21 mRNA expression in T47D cells and slightly increased PTEN and P21 expression in MCF-10A cells. Bcl-2 expression decreased in all of th...
European Online Journal of Natural and Social Sciences, 2014
Given the prevalence of breast cancer, the mortality of patients and the public's convenient access to the herbal extract of milk thistle, we decided to examine the effectiveness of this plant's components on the breast cancer cell line MCF-7. Silibinin is a naturally occurring flavonoid antioxidant found in the milk thistle. Recently, it has demonstrated potent, anti-proliferative effects against various malignant cell lines. In the present study, MCF-7 cells were incubated and treated with various concentrations of silibinin repeatedly. The degree of cell cytotoxicity depended on the dose of the milk thistle's extract and also on the duration of its exposure, imparting an inhibitory effect on the viability of metastatic MCF-7 cells. Finally, the expression of apoptotic genes (BCL-2 and BAX) was assessed by Real time PCR. Cell viability and growth of MCF-7 cell lines were inhibited by silibinin. The results of the present study confirm the efficacy of the herbal supplement against breast cancer. Due to the nature of the product, its low cost and potential accessibility to the public, adding this herbal supplement to the human food diet may be effective in preventing and treating breast cancer.
Silibilin-Induces Apoptosis in Breast Cancer Cells by Modulating p53, p21, Bak and Bcl-xl Pathways
Asian Pacific journal of cancer prevention : APJCP, 2015
Nowadays herbal-derived medicines are attracting attention as new sources of drugs with few side effects. Silibinin is a flavonoid compound with chemotheraputic effects on different cancers such as examples in the prostate, lung, colon and breast. In the present study, the cytotoxic effects of silibinin on MCF7 breast cancer cells were investigated. Apoptosis was determined by flow cytometry and the impact of silibinin on the expression of pivotal genes including Bak, P53, P21, BRCA1, BCL-X1 and ATM was analyzed. Treatment for 24h had a significant dose-dependent inhibitory effect on cell growth (p<0.05) with dose- and time- dependent induction of apoptosis (p<0.05). In addition, there were significant increases in BRCA1, ATM, Bak and Bcl-XL gene expression at the mRNA level with different concentrations of silibinin for 24 or 48 h (p<0.05). Taken together, the results suggest that silibinin inhibits the proliferation and induces apoptosis of MCF-7 cells by down-regulating ...
Synergistic Anticancer Effects of Silibinin and Chrysin in T47D Breast Cancer Cells
Asian Pacific journal of cancer prevention : APJCP, 2017
Objective: Breast cancer is one of the most significant causes of female cancer death worldwide. Although several chemotherapeutics have been developed to treat this type of cancer, issues remain such as low survival rates and high reoccurrence after chemotherapy and radiotherapy. To explore a chemopreventive approach to enhancing breast cancer treatment efficacy, the antiproliferative effects of a combination of chrysin and silibinin, two herbal substances, in T47D breast cancer cells were assessed. Materials and Methods: Cytotoxicity of the agents singly and in combination was evaluated by MTT assay. Also, qRT-PCR was used to measure the expression levels of hTERT and cyclin D1 genes after 48 h treatment. Results: Cell viability assays revealed that chrysin or silibinin alone inhibited proliferation in a dose and time-dependent manner, and combining the drugs synergistically induced growth inhibition in the breast cancer cell line. The precise nature of this interaction was furthe...
Anti-cancer Effects of Silibinin: The Current Status in Cancer Chemoprevention
Natural Products for Cancer Chemoprevention
The naturally occurring flavonolignan Silibinin (also known as Silybin) is a bioactive constituent of silymarin isolated from the seeds of the milk thistle plant (Silybum marianum L. Gaernt.), a member of the Asteraceae family. The milk thistle plant is a part of the native vegetation in Southern Europe, Southern Russia, Asia Minor and Northern Africa. This multi-functional flavonolignan possesses strong hepatoprotective, cardioprotective, neuroprotective, immune-modulatory, antidotal and anti-neoplastic properties. To date, over 600 peer-reviewed research reports and limited clinical trials have evaluated the anti-oncogenic efficacy of silibinin to combat tumor growth, angiogenesis, and metastasis. As a promising agent, silibinin mediates a wide-range of potent chemopreventive and anti-cancer activities in several frequently diagnosed epithelial malignancies, including skin, colon, prostate and lung. In addition, several combinatorial anti-cancer strategies of silibinin with other therapeutics exhibit synergistic interactions to suppress drug-induced toxic effects and chemoresistance. In this chapter, the pre-clinical and clinical efficacy of silibinin and/or silymarin derivatives against several cancers will be reviewed. Moreover, the chapter will summarize silibinin effects on key signaling pathways, such as: transforming Growth Factor beta (TGFβ), epidermal growth factor receptor (EGFR), insulin-like growth factor-1 receptor (IGF-1R), and NF-κB (nuclear factor-kappa B), which are crucial to the anti-cancer activity of silibinin in cancer prevention, disease progression/recurrence and reversal of drug resistance.
Oncology Reports, 2004
Significant emphasis is being placed on combination chemotherapy of cancer using cytotoxic agents and naturally occurring chemopreventive agents, having different mechanisms of action with non-overlapping toxicity. In this regard, here we assessed whether a cancer preventive agent silibinin synergizes the therapeutic potential of doxorubicin (Dox), cisplatin or carboplatin, the chemotherapeutic drugs, in both estrogen-dependent and-independent human breast carcinoma, MCF-7 and MDA-MB468 cells, respectively. When tested alone, each of the four agents showed growth inhibition in both the cell lines in a dose-and a time-dependent manner. Based on their growth inhibitory effects, several combinations of silibinin (25-100 |LiM) with Dox (10-75 nM), cisplatin (0.2-2 |U.g/ml) or carboplatin (2-20 1-ig/ml) were next assessed for their synergistic, additive and/or antagonistic efficacy towards cell growth inhibition and apoptotic death. The strongest synergistic effects for cell growth inhibition [combination index (CI) 0.35 for MCF-7 and 0.45 for MDA-MB468 cells] were evident at a silibinin dose of 100 |_iM plus 25 nM Dox, in both the cell lines. Most of the CIs for other combinations of these three drugs with silibinin also suggested strong synergistic effects for cell growth inhibition in both MCF-7 and MDA-MB468 cells. In quantitative apoptosis studies, combination of silibinin with Dox resulted in much stronger apoptotic death compared to each agent alone in both cell lines. In case of silibinin combination with cisplatin, it showed no additional apoptotic effect in either cell line. Similarly, silibinin plus carboplatin combination showed stronger apoptotic effect only in MCF-7 cells. Together, these results suggest a possible synergism between silibinin and conventional cytotoxic agents for
Silibinin – A Promising New Treatment for Cancer
Anti-Cancer Agents in Medicinal Chemistry, 2010
Silymarin and its major constituent, Silibinin, are extracts from the medicinal plant Silybum marianum (milk thistle) and have traditionally been used for the treatment of liver diseases. Recently, these orally active, flavonoid agents have also been shown to exert significant anti-neoplastic effects in a variety of in vitro and in vivo cancer models, including skin, breast, lung, colon, bladder, prostate and kidney carcinomas. The aim of the present review is to examine the pharmacokinetics, mechanisms, effectiveness and adverse effects of silibinin's anti-cancer actions reported to date in pre-clinical and clinical trials. The review will also discuss the results of current research efforts seeking to determine the extent to which the effectiveness of silibinin as an adjunct cancer treatment is influenced by such factors as histologic subtype, hormonal status, stromal interactions and drug metabolising gene polymorphisms. The results of these studies may help to more precisely target and dose silibinin therapy to optimise clinical outcomes for oncology patients.
Effect of Silibinin on Maspin and ERα Gene Expression in MCF-7 Human Breast Cancer Cell Line
Iranian journal of pathology, 2017
According to reports, a serine protease inhibitor (Maspin) suppresses metastasis, invasion and angiogenesis in breast and prostate cancers. Silibinin is a natural polyphenolic flavonoid with anti-cancer activity. We assessed the effects of silibinin on cell viability, maspin and ERα gene expression in MCF-7 cell line. The human MCF-7 breast cancer cell line was cultured in Dulbecco's Modified Eagle's Medium (DMEM) and treated with different concentrations of silibinin (100-600 μg/mL) for 24, 48 and 72 hours. The cytotoxic effect of silibinin on MCF-7 viability was determined using Methyl-Thiazolyl-Tetrazolium (MTT) assay by IC50 determination. The fold changes of Maspin and ERα expression were determined by reverse-transcription real-time Polymerase Chain Reaction (PCR). All experiments on the cells were performed in triplicates. The maximum inhibitory effect of silibinin on cell viability was observed at 600 μg/mL after 72-hour incubation (p = 0.001). Incubation of the cell...
Flavonoid, Silibinin, Inhibits Proliferation and Promotes Cell-Cycle Arrest of Human Colon Cancer
Journal of Surgical Research, 2007
Silibinin is the primary active component isolated from the crude seed extract, silymarin. It has been used as a dietary supplement for hepatoprotection for over 2000 years. Silibinin has been shown to be safe in multiple animal models and has had no significant adverse events in human studies. We investigated the potential for this nontoxic flavolignan to inhibit proliferation of human colon cancer.
Prostate cancer (PCA) is the most common cancer diagnosed in men and the second most common cause of death due to cancers after lung cancer. Metastasis of cancer cells involves multiple processes and various cytophysiological changes, including changed adhesion capability between cells and extracellular matrix (ECM) and damaged intercellular interaction. Silibinin, a naturally occurring flavonoid antioxidant found in the milk thistle, has recently been shown to have potent antiproliferative effect against various malignant cell lines. In the present study, PC-3 cells were incubated with various concentrations of silibinin for different times; then, cell cytotoxicity, cell adhesion and cell motility were assessed using MTT assay, cellematrix adhesion assay and cell migration assay, respectively. The results showed that silibinin exerted a dose-and time-dependent inhibitory effect on the viability, motility and adhesion of highly metastatic PC-3 cells. These observations indicate that silibinin can probably inhibit metastasis in PCA. Ó